|
|
Scheelev�gen 22, P.O. Box 724
Lund, 220 07 Sweden
phone:+46 46 19 20 00
fax:+46 46 19 11 22
|
|
| Symbol |
ACTI |
| Exchange |
Nasdaq |
| Founded |
0 |
| Employees |
|
|
|
| www.activebiotech.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Pharmaceuticals for fields in which the immune system plays a central role. |
|
| Management |
| Tomas Leanderson, President & CEO; Goran Forsberg, VP Investor Relations & Business Development; Hans Kolam, Chief Financial Officer; Helen Tuvesson, Head of Preclinical Development |
| |
|
|
|
|
|
|
| |
|
|
|
|
| Keywords |
| multiple sclerosis, lung, renal, pancreatic, cancer, autoimmune |
|
|
|
|
|
|
| Description |
|
Active Biotech is developing pharmaceuticals for medical fields in which the immune system plays a central role. The company focuses mostly on autoimmune/inflammatory diseases and cancer. To combat such pathologies Active Biotech employs innovative substances that modulate the human immune system. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members